Subcutaneous or intravenous administration significantly increases serum levels of bone formation markers, such as P1NP, ALP, and osteocalcin, and significantly decreases the level of serum C-terminal peptide (CTX), a bone resorption marker, in patients with osteoporosis [98]. The gene discussed is BGLAP; the disease is osteoporosis.